Will ClearPoint Neuro stock go up?

According to Danelfin AI, ClearPoint Neuro has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.95%) is -3.87% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for ClearPoint Neuro stock?

The ClearPoint Neuro target price is $18.74 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold ClearPoint Neuro stock right now?

ClearPoint Neuro has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.95%) is -3.87% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether ClearPoint Neuro stock is a good buy .

Is ClearPoint Neuro undervalued right now?

Based on analysts, the average price target downside for ClearPoint Neuro is 0.00% (1Y). According to Danelfin AI, ClearPoint Neuro has today an AI Score of 3/10 (Sell Rating).

What was the price range of ClearPoint Neuro stock over the past 12 months?

The ClearPoint Neuro stock price range over the past 12 months has been $8.66 - $29.6.

What is going on with ClearPoint Neuro stock in the last 3 months?

The ClearPoint Neuro stock performance in the last quarter has been +105.03%.

Does ClearPoint Neuro offer dividend payments?

No, ClearPoint Neuro does not currently pay dividends.

What is the current market capitalization of ClearPoint Neuro?

ClearPoint Neuro's market cap is $561.4M, as of 2026-07-03 08:00.

Clearpoint Neuro Inc (CLPT) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CLPT AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+0.78%
Stability and reliability of reported earnings
Size & Liquidity+0.17%
Company size and trading liquidity

Sentiment-2.99%
How analysts and the market view the stock
Volatility-0.70%
How much the stock price tends to fluctuate
Profitability-0.43%
Profitability and operating efficiency metrics
Momentum-0.39%
Direction and strength of recent price movements
Valuation-0.32%
How the stock is priced relative to its fundamentals

CLPT probability advantage of beating the market (3M):

-3.87%

AI Score

Sell

ClearPoint Neuro (CLPT) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -3.87% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CLPT (46.95%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CLPT probability advantage of beating the market (3M)-3.87%
CLPT probability of beating the market (3M)46.95%

CLPT probability advantage of beating the market (3M): -3.87%

The AI-powered overall analysis of ClearPoint Neuro (CLPT) is based on the 26 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CLPT:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-1.45%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.88%
Fundamental	Operating Cash Flow (Qtr Discrete)	-7.97		+0.78%
Technical	Chart Pattern (504d)	figure_90	N/A	+0.78%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	-0.68%
Technical	Maximum Volatility	9.95%		-0.65%
Technical	Chart Pattern (180d)	figure_73	N/A	-0.49%
Fundamental	Operating Profit Margin	-69.90%		-0.43%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.42%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	2.91		-0.42%
Technical	Upgrade to unlock			+0.39%
Sentiment	Upgrade to unlock			+0.38%
Technical	Upgrade to unlock			-0.32%
Fundamental	Upgrade to unlock			-0.32%
Sentiment	Upgrade to unlock			-0.32%

Rest of Alpha Signals: -0.65%

CLPT probability advantage of beating the market (3M)Total:-3.87%
CLPT AI Score

Significant changes Vs previous day

CLPT Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$18.74
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

CLPT Proven Sell Signal & Price Forecast

This is the price chart for CLPT from January 3, 2026 until today. The chart indicates, in red, the 0 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CLPT Average Past Performance & Loss Rate

Three months after its 459 Sell signals since July 2026, CLPT had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

459 Past CLPT Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+18.77%
Average Alpha				+12.12%
Loss Rate (% Negative Perf.)				48.16%
% Negative Alpha				50.86%

CLPT Frequently Asked Questions

Will ClearPoint Neuro stock go up?
According to Danelfin AI, ClearPoint Neuro has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.95%) is -3.87% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for ClearPoint Neuro stock?
Is it a good time to buy, sell, or hold ClearPoint Neuro stock right now?
Is ClearPoint Neuro undervalued right now?
What was the price range of ClearPoint Neuro stock over the past 12 months?
What is going on with ClearPoint Neuro stock in the last 3 months?
Does ClearPoint Neuro offer dividend payments?
What is the current market capitalization of ClearPoint Neuro?

Clearpoint Neuro Inc Company Profile

Clearpoint Neuro, Inc. functions as a medical technology enterprise predominantly in the United States, with its primary focus on the development and market introduction of platforms that aid in executing minimally invasive neurological surgeries under the guidance of magnetic resonance imaging (MRI). Within their suite of offerings is the ClearPoint system – a cutting-edge, consolidated solution tailored for accurately positioning deep brain stimulation electrodes, conducting needle biopsies and introducing laser catheters into the brain as well as safely administering pharmaceutical substances.

Additionally, the company seeks to amplify its impact through strategic partnerships, evidenced by license arrangements and cooperative agreements with formidable entities such as Clinical Laserthermia Systems AB; Royal Philips N.V., UCB Biopharma SRL; and notable academic institutions like the University of California and San Francisco. Moreover, it maintains a product development and licensing agreement with NE Scientific, LLC.

Initially established under the banner MRI Interventions, Inc., the firm formally adopted its current name - ClearPoint Neuro, Inc. - in February 2020. The origination of ClearPoint Neuro dates back to 1998. Now proudly ensconced in their Solana Beach base in sunny California, they continue to engineer impactful breakthroughs at this primary seat of operations.

Sector:Health Care
Country:United States
Industry:Health Care Equipment & Supplies
Address:120 S. Sierra Avenue, Suite 100, Solana Beach
Employees:172
Website:clearpointneuro.com

Pros

High switching costs for integrated neuro-navigation systems

Proprietary technology in MRI-guided neuro-interventions

Increasing prevalence of neurological disorders driving demand

Recurring revenue from platform disposables and software licenses

Rigorous regulatory approval process creating entry barriers

Cons

Substantial capital expenditure for research and development

Exposure to healthcare reimbursement policy changes

Growth dependent on partner drug therapy clinical success

Competition from diversified medical technology incumbents

Hospital capital equipment budget cyclicality

CLPT Stock AI Analysis